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Summary A pathological review was carried out on 600 patients with breast carcinoma entered into the
'Nolvadex'* Adjuvant Trial Organisation (NATO) study. The tumours were graded histologically and these
results were compared with the oestrogen receptor (ER) status of the tumours, the numbers of recurrences
and the length of survival of the patients. It was found that histological grading was predictive both in terms
of events and survival, and correlates significantly with oestrogen receptor status; within histological grades I
and II, patients receiving 'Nolvadex' had fewer events and deaths compared with patients in the control
group. For patients with grade III tumours qualitatively it was in the same direction as the benefit obtained
in patients with grade I and II tumours.
The patients recruited into a multicentre randomised con-
trolled trial of tamoxifen ('Nolvadex') as a single adjuvant
agent after mastectomy for early breast cancer have now
been followed up for a maximum of 8 years ('Nolvadex'
Adjuvant Trial Organisation (NATO), 1983, 1985, 1987).
Premenopausal women with positive axillary nodes and
postmenopausal women aged 75 or less with either positive
or negative axillary nodes were randomised to receive either
tamoxifen 10mg twice daily for 2 years or to no systemic
therapy until the time of relapse. In 46% of the trial
population the primary tumour specimens were assayed for
oestradiol receptor (ER) content. Published results have
already demonstrated that event-free and actuarial survival is
prolonged in the group receiving adjuvant tamoxifen.
Further, a Cox's multivariate analysis has failed to identify
any subgroup based on nodal, menopausal or ER status,
that has a preferential benefit from this drug ('Nolvadex'
Adjuvant Trial Organisation, 1983, 1985). The result based
on the ER analysis is counter-intuitive and therefore requires
closer scrutiny. Attempts to dismiss the result as an artifact
of faulty ER assay are not valid because the proportion of
patients with ER positive tumours and the prognostic signifi-
cance of a positive result parallel the data from many other
large-scale studies (McGuire et al., 1975; Wallgren et al.,
1984; Rose et al., 1985). A more fertile line to pursue might
be to consider the ER status as predicting quantitative
differences in outcome rather than absolute qualitative
differences. If this is the case, the correct result might be
obscured by power considerations in a trial reduced to less
than 600 cases where ER status of the primary tumour was
known. As histological grade has been shown to correlate
with prognosis and ER status in breast carcinoma (Bloom &
Richardson, 1957; Bloom, 1962; Elston et al., 1980) a
reanalysis of the clinical outcome of the treatment with
respect to this variable and to the ER status of the primary
tumour has been performed in an attempt to throw addi-
tional light on the current findings.
Methods
All centres who entered patients into the NATO trial were
requested to provide the original histological slides of the
primary tumour.
The tumours were graded histopathologically according to
*'Nolvadex' is a trade mark property of ICI Pharmaceuticals
Division PLC.
Correspondence: M. Baum.
Received 24 November 1987; and in revised form, 8 March 1988.
the well known Bloom & Richardson criteria (1957) in which
tubular differentiation, nuclear pleomorphism and the
presence of mitotic figures are each scored on a three point
scale; cases with a score of 3-5 being allocated to Grade, I
6-7 to Grade II and 8-9 to Grade III.
Statistical analysis of the outcome was based on an
'intention to treat' policy using two separate end points. One
end point was first recurrence of breast cancer (including
cancer in the contralateral breast) or death without pre-
viously confirmed recurrence of disease ('events'). The other
end point was overall survival. Log rank tests (Peto et al.,
1976, 1977) were used to assess the statistical significance of
the difference between treatment groups and between histo-
logical grades with respect to time to an event and overall
survival time.
Results
Of the 1,285 patients entered in the NATO trial, slides were
eventually received from 600 patients. Grading was possible
in 546 cases (91%) and in 256 cases (47%) where tumour
oestrogen receptor had also been measured. 282 of the 546
patients (52%) had been treated with tamoxifen.
The treated and untreated groups were similar in the
distribution of tumour grade (Table I). Tables IIA and IIB
and Figure 1 show that histological grade was predictive for
both events (P<0.0001) and deaths (P<0.0001). In the case
where the oestrogen receptor content of the primary tumour
was known in addition to the histological grade, (Table III)
there was little difference in oestrogen receptor content
between grade I and grade II tumours and, taken together
56% (117/208) of these tumours had over 30fmolmg-1
cytosol protein while in contrast 37% (18/48) of grade III
tumours had this level of oestrogen receptor. This difference
is statistically significant (P=0.03). Table IV and Figure 2
compare events and overall survival between the tamoxifen-
treated and control patients in each tumour grade. These
Table I Distribution of the 546 cases by treatment allocated and
histological grade of the primary tumour
Histological grade
1 2 3
No. % No. % No. % Totals
'Nolvadex' 101 36 141 50 40 14 282
No treatment 88 33 136 52 40 15 264
Totals 189 277 80 546
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Table 11(A) Events according to histological grade: compari-
son of observed and expected events, i.e. recurrences and
deaths without previously confirmed recurrence. (Stratified by
menopausal and nodal status and treatment)
Observed Expected OIE
Number events events ratio
Grade ofpatients (0) (E) (OIE)
I 188 68 86.8 0.78
II 273 121 126.1 0.96
III 78 54 30.1 1.79
Totals 539 243 243.0
X2=23.81; P= <0.0001.
Table 11(B) Survival according to histological grade: com-
parison of observed and expected deaths. (Stratified by
menopausal and nodal status and treatment)
Observed Expected O/E
Number events events ratio
Grade ofpatients (0) (E) (O/E)
I 188 49 69.1 0.71
II 273 96 101.0 0.95
III 78 50 24.9 2.01
Totals 539 195 195.0
X2 =32.31; P= <0.0001.
Table III Oestrogen Receptor Status in 256 cases
by histological grade
Oestrogen Receptor Values (fmoll-1)
<30 30+
Grade No. % No. % Totals
I 32 42 44 58 76
II 59 45 73 55 132
III 30 63 18 37 48
Totals 121 135 256
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Figure 1 Comparison of histological grades.
Table IV(A) The 539 cases by treatment: comparison of observed
and expected events, i.e. recurrences and deaths in each histological
grade. (Stratified by menopausal and nodal status and treatment)
Observed Expected
Number events events Ratio
Grade ofpatients (0) (E)
I 'Nolvadex' 101 28 38.0 0.74
No treatment 87 40 30.0 1.33
II 'Nolvadex' 139 49 66.9 0.73
No treatment 134 72 54.1 1.33
III 'Nolvadex' 38 26 27.0 0.96
No treatment 40 28 27.0 1.03
Table IV(B) The 539 cases by treatment: comparison of observed
and expected deaths in each histological grade. (Stratified by
menopausal and nodal status and treatment)
Observed Expected
deaths deaths Ratio
Grade Number (0) (E) (OIE)
I 'Nolvadex' 101 22 26.3 0.84
No treatment 87 27 22.7 1.19
II 'Nolvadex' 139 39 51.6 0.76
No treatment 134 57 44.4 1.28
III 'Nolvadex' 38 25 25.2 0.99
No treatment 40 25 24.8 1.01
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Figure 2 Effect of 'Nolvadex' within histological grades.
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reveal that the observed to expected ratios are less than one
in each of the treated groups indicating a treatment benefit
in each tumour grade, although the difference in ratios
between the treated and untreated groups is less for grade III
than for either grades I or II.
Discussion
These results demonstrate very clearly that histological grad-
ing is predictive in terms of events and survival. These
findings agree with results from other large studies concern-
ing the prognosis of breast cancer (Wallgren et al., 1984;
Rose et al., 1985). Histological grading is often criticised
because of its subjective nature and observer variation.
Furthermore, the histological specimen itself may not be
truly representative of the tumour as a whole. Nevertheless,
with one observer studying all 546 sections we are confident
that the subsequent interpretations of the data are secure.
The relatively high number of grade I tumours in the sample
might reflect random bias of tissue samples available for
analysis or the disproportionate number of node negative
cases in the trial as a whole (NATO, 1983).
For the purpose of classifying oestradiol receptor status in
this study, a cut-off point of 30fmolmg-1 cytosol protein
was chosen as this represented a median value for the trial as
a whole. Using lower values of cut-off to discriminate
between positive and negative tumours does not materially
affect the result, although it weakens statistical comparisons.
At a 30fmolmg-1 cytosol protein cut-off point there is little
difference between grades I and II but histological grade III
tumours were almost twice as likely to be receptor negative
than receptor positive, according to our definition. There
was thus a clear statistically significant difference in ER
content between grades I and II combined and grades III,
adding further support to previous observations showing a
correlation between histological grade and oestrogen recep-
tor status (Elston et al., 1980).
The results indicate that adjuvant tamoxifen may be of
greatest benefit in the better differentiated (Grades I and II)
tumours which are also the tumours likely to have a greater
oestradiol receptor content. This result provides some sup-
port for the notion that the differences in outcome from
adjuvant tamoxifen between different biological subsets of
breast cancer is one of magnitude rather than kind. Para-
doxically, the overview analysis of all trials of adjuvant
tamoxifen (Peto, personal communication) has suggested
that the relative risk reductions, based on lymph node status,
are constant, thus the greater the risk of relapse the greater
the absolute benefit of adjuvant tamoxifen.
Clearly, however, such detailed advice to clinicians must
await analyses on histological grading from other adjuvant
tamoxifen trials.
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